BLAINTRAVENOUSINJECTABLEPriority Review
Approved
Sep 2022
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
SPEVIGO (spesolimab-sbzo) by Boehringer Ingelheim is interleukin-36 receptor antagonists [moa]. First approved in 2022.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SPEVIGO (spesolimab-sbzo) is an interleukin-36 receptor antagonist administered intravenously for the treatment of generalized pustular psoriasis. This biologic works by blocking IL-36 signaling, a key driver of inflammatory cascade in pustular skin conditions. It represents a novel mechanism addressing an underserved patient population with severe, rapidly progressive disease.
$0.002BPart D
PeakEarly-stage product in peak lifecycle phase with modest Part D spending ($2M in 2023); commercial team focused on niche indication expansion and payer access strategies.
Mechanism of Action
Interleukin-36 Receptor Antagonists
Pharmacologic Class:
Interleukin-36 Receptor Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
SPEVIGO offers a specialized career path in rare disease commercialization with deep HCP and payer engagement. The narrow but underserved patient population and first-mover advantage create strong differentiation for individuals building expertise in niche immunology and market access.
Brand ManagerMedical Science Liaison
Worked on SPEVIGO at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.